AptaBio Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	3,361	323.87	48.35
Revenue Growth (YoY)	937.76%	569.80%	-
Cost of Revenue	3,087	262.8	11.15
Gross Profit	273.69	61.06	37.21
Selling, General & Admin	3,893	3,385	2,788
Research & Development	14,591	12,380	6,197
Other Operating Expenses	113.05	130.03	74.48
Operating Expenses	20,989	16,965	9,544
Operating Income	-20,715	-16,904	-9,507
Interest Expense	-3,401	-1,183	-4.49
Interest & Investment Income	2,296	1,984	1,572
Earnings From Equity Investments	-625.93	-4.19	-
Currency Exchange Gain (Loss)	-252.8	-29.52	-14.43
Other Non Operating Income (Expenses)	-4,651	1,688	42.49
EBT Excluding Unusual Items	-27,350	-14,448	-7,911
Gain (Loss) on Sale of Investments	-452.59	-244.29	-2,654
Pretax Income	-27,803	-14,692	-10,565
Income Tax Expense	1,575	-2,630	-
Net Income	-29,378	-12,062	-10,565
Net Income to Common	-29,378	-12,062	-10,565
Shares Outstanding (Basic)	24	23	22
Shares Outstanding (Diluted)	24	23	22
Shares Change (YoY)	3.83%	1.72%	-
EPS (Basic)	-1248.00	-532.00	-474.00
EPS (Diluted)	-1248.00	-532.00	-474.00
Free Cash Flow	-12,400	-15,440	-7,874
Free Cash Flow Per Share	-526.76	-681.01	-353.27
Gross Margin	8.14%	18.86%	76.95%
Operating Margin	-616.35%	-5219.25%	-19661.23%
Profit Margin	-874.09%	-3724.24%	-21849.26%
Free Cash Flow Margin	-368.94%	-4767.39%	-16284.04%
EBITDA	-20,184	-16,364	-9,022
D&A For EBITDA	531.35	539.11	484.62
EBIT	-20,715	-16,904	-9,507
Advertising Expenses	9	3	7.07

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.